0001209191-20-055041.txt : 20201016
0001209191-20-055041.hdr.sgml : 20201016
20201016154955
ACCESSION NUMBER: 0001209191-20-055041
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201014
FILED AS OF DATE: 20201016
DATE AS OF CHANGE: 20201016
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Loven Jakob
CENTRAL INDEX KEY: 0001753644
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39592
FILM NUMBER: 201243940
MAIL ADDRESS:
STREET 1: C/O ARVINAS, INC., 5 SCIENCE PARK
STREET 2: 395 WINCHESTER AVENUE
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kronos Bio, Inc.
CENTRAL INDEX KEY: 0001741830
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1300 S. EL CAMINO REAL
STREET 2: SUITE 300
CITY: SAN MATEO
STATE: CA
ZIP: 94402
BUSINESS PHONE: 212-871-7920
MAIL ADDRESS:
STREET 1: 1300 S. EL CAMINO REAL
STREET 2: SUITE 300
CITY: SAN MATEO
STATE: CA
ZIP: 94402
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-10-14
0
0001741830
Kronos Bio, Inc.
KRON
0001753644
Loven Jakob
C/O KRONOS BIO, INC.
1300 SO. EL CAMINO REAL, SUITE 300
SAN MATEO
CA
94402
1
0
0
0
Common Stock
2020-10-14
4
C
0
1376313
A
1376313
I
See footnote
Common Stock
2020-10-14
4
C
0
169031
16.15
A
1545344
I
See footnote
Series A Preferred Stock
2020-10-14
4
C
0
1304563
D
Common Stock
1376313
0
I
See footnote
Convertible Promissory Note
16.15
2020-10-14
4
C
0
2729859.81
0.00
D
2022-02-20
Common Stock
169031
0
I
See footnote
Each share of Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
The securities are held by Nextech V Oncology S.C.S, SICA-SIF ("Nextech V"). The reporting person currently serves as a member of the leadership team at Nextech Invest AG ("Nextech AG"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering.
/s/ David Tanen, Attorney-in-Fact
2020-10-16